creutzfeldt-jakob

Creutzfeldt-Jakob Disease (CJD)

Introduction

creutzfeldt-jakob-disease (CJD) is a progressive neurodegenerative disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches. [@geschwind2015]

Overview

Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE) or prion-disease. It is characterized by the accumulation of abnormal prion-protein (PrP^Sc) in the brain, leading to spongiform degeneration, neuronal loss, and astrocytic gliosis. CJD is the most common human Prion Disease, with an annual incidence of approximately 1-2 cases per million people worldwide (~350 cases annually in the United States) ([Geschwind, 2015](https://doi.org/10.1212/CON.0000000000000251)). [@prusiner1982]

The disease was first described independently by German neurologists Hans Gerhard Creutzfeldt in 1920 and Alfons Maria Jakob in 1921. [The connection to prions was not established until Stanley Prusiner's groundbreaking work in the 1980s, for which he received the Nobel Prize in Physiology or Medicine in 1997 ([Prusiner, 1982)](https://doi.org/10.1126/science.6801762)). The identification of variant CJD (vCJD) in 1996 provided the first evidence that bovine spongiform encephalopathy (BSE) could cross species barriers to infect humans ([Will et al., 1996](https://doi.org/10.1016/S0140-6736(96)91412-9)). [@will1996]

Types of Creutzfeldt-Jakob Disease

Creutzfeldt-Jakob Disease (CJD)

Introduction

creutzfeldt-jakob-disease (CJD) is a progressive neurodegenerative disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches. [@geschwind2015]

Overview

Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE) or prion-disease. It is characterized by the accumulation of abnormal prion-protein (PrP^Sc) in the brain, leading to spongiform degeneration, neuronal loss, and astrocytic gliosis. CJD is the most common human Prion Disease, with an annual incidence of approximately 1-2 cases per million people worldwide (~350 cases annually in the United States) ([Geschwind, 2015](https://doi.org/10.1212/CON.0000000000000251)). [@prusiner1982]

The disease was first described independently by German neurologists Hans Gerhard Creutzfeldt in 1920 and Alfons Maria Jakob in 1921. [The connection to prions was not established until Stanley Prusiner's groundbreaking work in the 1980s, for which he received the Nobel Prize in Physiology or Medicine in 1997 ([Prusiner, 1982)](https://doi.org/10.1126/science.6801762)). The identification of variant CJD (vCJD) in 1996 provided the first evidence that bovine spongiform encephalopathy (BSE) could cross species barriers to infect humans ([Will et al., 1996](https://doi.org/10.1016/S0140-6736(96)91412-9)). [@will1996]

Types of Creutzfeldt-Jakob Disease

Sporadic CJD (sCJD)

Sporadic CJD accounts for approximately 85-90% of all cases and occurs spontaneously without known genetic or environmental-risk-factors ([Parchi et al., 1999](https://doi.org/10.1002/1531-8249(199912)46:6<731::AID-ANA2>3.0.CO;2-Y)): [@parchi1999]

• Incidence: ~1-2 per million per year
• Mean age of onset: 60-65 years
• Median survival: 4-6 months (90% die within 1 year)
• Cause: Unknown; possibly spontaneous misfolding of PrP^C or somatic PRNP mutations

| Subtype | Frequency | Clinical Features | Duration | [@windl1999]
|---------|-----------|-------------------|----------| [@caughey2003]
| MM1/MV1 | ~70% | Classic: rapid dementia, myoclonus, EEG changes | 3-4 months | [@budka1995]
| VV2 | ~16% | Cerebellar ataxia, later dementia | 6-7 months | [@zerr2009]
| MV2 | ~9% | Ataxia, dementia, longer course | 17-18 months | [@mcguire2012]
| MM2-cortical | ~2% | Progressive dementia, longer course | 15-16 months | [@raymond2019]
| MM2-thalamic | ~2% | Insomnia, dysautonomia (sporadic fatal insomnia) | 16 months | [@mead2003]
| VV1 | ~1% | Early onset, progressive dementia | 15-21 months | [@bhatt2024]

Familial CJD (fCJD)

Familial CJD comprises about 10-15% of cases and follows autosomal dominant inheritance with PRNP gene mutations on chromosome 20p13 ([Windl et al., 1999](https://doi.org/10.1007/s004150050341)): [@collins2004]

• E200K mutation: Most common worldwide; similar clinical presentation to sCJD but with younger onset
• D178N with valine at codon 129: Produces familial CJD phenotype
• D178N with methionine at codon 129: Produces fatal familial insomnia (FFI) phenotype
• V210I, R208H, E196K: Other pathogenic mutations with varying penetrance

Iatrogenic CJD (iCJD)

Iatrogenic CJD results from accidental transmission of prions through medical procedures ([Brown et al., 2000](https://doi.org/10.1212/WNL.55.8.1075)): [@national]

• Dura mater grafts (Lyodura): Largest source; primarily reported from Japan
• Pituitary-derived growth hormone: Over 200 cases worldwide before recombinant hormone became available
• Corneal transplants: Rare cases documented
• Contaminated neurosurgical instruments: Historical cases; standard autoclaving is insufficient for prion inactivation
• Blood transfusion: Four confirmed cases of vCJD transmission in the UK

Variant CJD (vCJD)

Variant CJD was first identified in 1996 in the UK and is causally linked to bovine spongiform encephalopathy (BSE) ([Will et al., 1996](https://doi.org/10.1016/S0140-6736(96)91412-9)):

• Median age of onset: 28 years (significantly younger than sCJD)
• Duration: 12-14 months
• Cumulative cases: ~230 worldwide (majority in UK)
• Clinical features: Prominent early psychiatric symptoms (depression, anxiety, behavioral changes) and painful sensory symptoms preceding dementia and ataxia
• Genetic susceptibility: All definite clinical cases to date have been methionine homozygous (MM) at codon 129

Pathophysiology

Prion Protein Conversion

The central event in CJD is the conformational conversion of normal PrP^C into PrP^Sc. This post-translational process transforms the alpha-helix-rich structure of PrP^C into a beta-sheet-dominated conformation that is insoluble, protease-resistant, and self-propagating ([Caughey & Lansbury, 2003](https://doi.org/10.1146/annurev.neurosci.26.010302.081142)).

Mechanisms of Neuronal Damage

Multiple interconnected pathways contribute to neurodegeneration:

Clinical Presentation

Core Clinical Triad

Additional Neurological Features

• Cortical blindness (Heidenhain variant): Visual disturbances as the presenting feature
• Pyramidal signs: Spasticity, hyperreflexia, Babinski sign
• Extrapyramidal signs: Parkinsonism, dystonia, choreoathetosis
• Speech dysfunction: Dysarthria progressing to mutism
• Seizures: Focal or generalized, in ~10-15% of cases

Psychiatric and Behavioral Symptoms

Depression, anxiety, apathy, agitation, and psychosis may occur, particularly early in vCJD. Initial psychiatric presentation is common in vCJD and younger patients, often delaying the correct diagnosis by weeks to months.

Diagnosis

Updated Diagnostic Criteria

The updated criteria ([Zerr et al., 2009](https://doi.org/10.1093/brain/awp191)) classify sCJD as:

• Definite: Neuropathological confirmation with PrP^Sc detection by immunohistochemistry or Western blot
• Probable: Progressive dementia + at least 2 of 4 clinical features (myoclonus, visual/cerebellar, pyramidal/extrapyramidal, akinetic mutism) + supportive investigation (EEG, MRI, or CSF)
• Possible: Progressive dementia + clinical features but lacking supportive investigation findings

Diagnostic Investigations

• Diffusion-weighted imaging (DWI): Cortical ribboning and/or caudate/putamen hyperintensity; sensitivity ~92%, specificity ~95%
• FLAIR: May show similar patterns but less sensitive than DWI
• Cortical atrophy: Progressive with disease

• Ultrasensitive assay detecting PrP^Sc seeding activity in CSF
• Sensitivity ~92%, specificity ~100% for sCJD
• Can be performed on nasal brushings (sensitivity ~97%) and skin biopsies
• Has transformed pre-mortem diagnosis ([McGuire et al., 2012](https://doi.org/10.1002/ana.23590))

• 14-3-3 protein: Sensitivity ~85-95%, specificity ~75-85%; reflects rapid neuronal destruction
• Total tau]: Markedly elevated (>1,150 pg/mL); correlates with disease progression
• nfl-protein (NfL))): Elevated; reflects axonal damage
• RT-QuIC: See above

Treatment

Current Management

There is no cure for CJD. All [treatments are supportive and palliative:

• Myoclonus: Clonazepam (first-line), sodium valproate, levetiracetam
• Seizures: Standard antiepileptic medications
• Pain: Standard analgesic protocols; opioids for severe pain
• Psychiatric symptoms: Cautious use of antipsychotics and anxiolytics
• Dysphagia: Swallowing assessment; PEG tube consideration
• Physical therapy: Maintain mobility and comfort
• Palliative care: Early involvement of palliative care teams
• Family support: Genetic counseling for familial cases; psychological support

Experimental Therapeutic Approaches

• Efavirenz (anti-HIV drug): Extended survival in scrapie-infected mice via brain cholesterol regulation ([JCI Insight, 2024](https://doi.org/10.1172/jci.insight.190296))
• Anle138b: Oligomer modulator with preclinical efficacy

Past [clinical trials of quinacrine, pentosan polysulfate, and doxycycline have not demonstrated clear efficacy.

Brain-Computer Interface Therapy

Brain-computer interfaces (BCIs) offer potential applications for monitoring and supportive care in Creutzfeldt-Jakob Disease, primarily for patients with advanced disease who lose motor and communication abilities[@wolpaw2004].

Current Applications

• Cognitive monitoring: EEG-based BCI can track cortical function and detect changes in neural activity
• Communication support: For patients in locked-in state or with severe motor impairment
• Neurophysiological biomarkers: Neural signals may aid in disease monitoring
• Palliative care integration: BCI for environmental control in hospice settings

Emerging Technologies

• Rapid cognitive assessment: BCI-based tools for quick cognitive evaluation
• Neural biomarker development: Using BCI signals for prion disease detection
• Home monitoring systems: Non-invasive BCI for continuous patient monitoring

Clinical Evidence

BCI applications in CJD are primarily exploratory. The rapid progression of the disease limits therapeutic interventions, but BCI for communication in the terminal phase has been studied. EEG abnormalities in CJD are well-documented, providing a basis for neural monitoring approaches[@collins2000].

Cross-References

• EEG Brain-Computer Interface
• Brain-Computer Interface Technologies
• Non-Invasive Home BCI Technology

[@collins2000]: Collins JD, et al. EEG findings in Creutzfeldt-Jakob disease. Clinical Neurophysiology. 2000;111(11):1960-1967. Available from: https://doi.org/10.1016/s1388-2457(00)00441-5

Differential Diagnosis

Conditions that may mimic CJD include:

• alzheimers (rapidly progressive variant)
• lewy-body-dementia (rapid cognitive decline with movement disorder)
• ftd (behavioral variant)
• Autoimmune encephalitis (anti-nmda-receptor receptor] receptor] receptor, anti-LGI1, anti-CASPR2)
• Paraneoplastic neurological syndromes
• CNS vasculitis
• Viral encephalitis (HSV, EBV)
• Hashimoto's encephalopathy (steroid-responsive encephalopathy)
• Non-convulsive status epilepticus
• Metabolic encephalopathies (hepatic, uremic)

Epidemiology

| Feature | sCJD | fCJD | iCJD | vCJD |
|---------|------|------|------|------|
| Frequency | 85-90% | 10-15% | <1% | <1% |
| Mean onset age | 60-65 yrs | 50-60 yrs | Variable | 28 yrs |
| Median survival | 4-6 months | Variable | Variable | 12-14 months |
| Sex ratio (M:F) | 1.2:1 | 1:1 | Variable | ~1:1 |
| Cause | Spontaneous | PRNP mutation | Medical exposure | BSE prions |

Genetics

The PRNP gene polymorphisms profoundly influence disease susceptibility and phenotype:

• Codon 129 polymorphism: The most important genetic modifier. Homozygosity (MM or VV) increases risk for sCJD and vCJD. ~70% of sCJD patients are MM at codon 129 versus ~40% in the general European population.
• Pathogenic mutations: Over 50 mutations identified (E200K, D178N, V210I, P102L, etc.)
• Protective heterozygosity: MV heterozygosity at codon 129 appears protective against both sCJD and vCJD ([Mead et al., 2003](https://doi.org/10.1073/pnas.0937733100))

Prognosis

CJD is uniformly fatal:

• sCJD: ~90% of patients die within 1 year of symptom onset; median survival 4-6 months
• fCJD: Variable; some forms (E200K) similar to sCJD; others (P102L/GSS) may survive 2-10 years
• vCJD: Median survival 12-14 months
• Death typically results from pneumonia, other infections, or central respiratory failure in the terminal akinetic mutism stage

Background

The study of Creutzfeldt Jakob Disease (Cjd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

• [Diseases Index
• [Prion Diseases
• [Neurodegeneration
• [Dementia

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

Recent advances in Creutzfeldt-Jakob Disease have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Prion Disease Pathogenesis

CJD Pathogenesis Overview

References

[DOI:10.1212/CON.0000000000000251](https://doi.org/10.1212/CON.0000000000000251)